Detailed instructions and medication guide for pirtobrutinib

Pirtobrutinib (Pirtobrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor. It is a new generation of targeted therapy drugs and is mainly used to treat certain Bcell malignancies, such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and other related lymphomas. As a BTK inhibitor, pitobrutinib inhibits the BTK signaling pathway and blocks the abnormal proliferation and survival of B cells, thereby inhibiting tumor growth. The following is the detailed package insert and dosing guide for Pitobrutinib.

1. Indications

Pitobrutinib is mainly suitable for the treatment of the following diseases:

1.Mantle cell lymphoma (MCL), especially in patients who have failed or are intolerant to at least one BTK inhibitor.

2.Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

3.OtherB cell-associated lymphomas, including marginal zone lymphoma (MZL), etc.

2. Usage and dosage

Pitobrutinib is usually administered orally. The recommended dose is 200 mg once daily, continuously. It is recommended to take the medicine at a fixed time every day, with food or on an empty stomach.

Treatment should be continued until disease progression or until the patient develops intolerable adverse effects. If serious adverse reactions occur, dose reduction, suspension or termination of treatment should be considered based on the specific circumstances.

3. Medication precautions

1.Drug monitoring

During treatment, hematological indicators, liver and kidney function, and electrocardiogram should be monitored regularly to detect potential side effects in a timely manner.

2.Drug interactions

Pitobrutinib is mainly metabolized by the liver, especially theCYP3A4 enzyme system. Combined and powerfulCYP3A4Inhibitors (such as ketoconazole, clarithromycin) may increase the plasma concentration of pitobrutinib and increase the risk of toxicity, so they should be used together with caution. Concomitant use of CYP3A4 inducers (such as rifampicin, carbamazepine) may reduce its efficacy.

3.Special groups

Pregnant and breastfeeding women should avoid using pitobrutinib because its safety has not been established. People with severely impaired liver and kidney function should use it with caution and adjust the dosage under the guidance of a doctor.

4.Adverse reaction management

Common adverse reactions include fatigue, diarrhea, nausea, bleeding tendency, thrombocytopenia, infection, etc. Patients should pay close attention to physical changes and report to their doctor promptly. Severe side effects may require temporary discontinuation or dose adjustment.

5. Medication compliance

Pitobrutinib is an oral drug. Patients should adhere to the medication as directed by the doctor and are not allowed to stop taking the medication or change the dose on their own to ensure the efficacy.

4. Adverse reactions

The safety profile of pitobrutinib is generally good, but some patients may experience the following adverse reactions:

1.Hematological reactions: including anemia, thrombocytopenia, and neutropenia, which may lead to an increased risk of bleeding or infection.

2.Digestive system reactions: such as diarrhea, nausea, vomiting, and loss of appetite.

3.Bleeding events: Mild to moderate bleeding may occur in a small number of patients, and severe bleeding is rare.

4.Cardiovascular system: high blood pressure and arrhythmia may occur.

5.Risk of infection: Due to suppressed immune function, patients are prone to bacterial or viral infections.

6.Others: fatigue, rash, joint pain, etc.

5. Contraindications

Contraindicated in patients allergic to pitobrutinib or its components.

It is prohibited for pregnant women and should be used with caution by lactating women.

When patients have severe liver and kidney dysfunction, they should be used with caution and the dose should be adjusted if necessary.

6. Drug storage

Pitobrutinib should be stored in a dry, cool place, away from direct sunlight, and stored at room temperature. Keep out of reach of children.

Pittobrutinib, as a new generation of BTK inhibitors, has shown good efficacy and safety in the treatment of B cell malignancies. Patients should strictly abide by medical instructions during use, monitor their physical condition regularly, and adjust treatment plans in a timely manner. Stay vigilant about potential adverse reactions to ensure safe and effective treatment. With the accumulation of more clinical data in the future, pitobrutinib is expected to become a key treatment option for more patients.

Reference materials:https://www.drugs.com/